NSPR (InspireMD, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by NSPR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-29 | Paul Stuka | Director | Buy | — | — |
| 2026-05-21 | Shane Thomas Gleason | Chief Commercial Officer | Sell | — | — |
| 2026-05-15 | Paul Stuka | Director | Buy | — | — |
| 2026-05-13 | Marvin Slosman | CEO and President | Buy | — | — |
| 2026-05-13 | Paul Stuka | Director | Buy | — | — |
| 2026-05-12 | Paul Stuka | Director | Buy | — | — |
| 2026-05-08 | Paul Stuka | Director | Buy | — | — |
| 2026-05-08 | GARY S ROUBIN | Director | Buy | — | — |
| 2026-05-08 | Scott R. Ward | Director | Buy | — | — |
| 2026-02-23 | Paul Stuka | Director | Buy | — | — |
| 2026-02-02 | Shane Thomas Gleason | Chief Commercial Officer | Sell | — | — |
| 2026-01-16 | Michael A Lawless | Chief Financial Officer | A | — | — |
| 2026-01-16 | Marvin Slosman | CEO and President | A | — | — |
| 2026-01-16 | GARY S ROUBIN | Director | A | — | — |
| 2026-01-16 | Andrea Tommasoli | Chief Operating Officer | A | — | — |
| 2026-01-16 | Scott R. Ward | Director | A | — | — |
| 2026-01-16 | MICHAEL BERMAN | Director | A | — | — |
| 2026-01-16 | RAYMOND W COHEN | Director | A | — | — |
| 2026-01-16 | Danny L. Dearen | Director | A | — | — |
| 2026-01-16 | Paul Stuka | Director | A | — | — |
| 2026-01-16 | Shane Thomas Gleason | Chief Commercial Officer | A | — | — |
| 2025-12-31 | Kathryn Arnold | Director | A | — | — |
| 2025-12-11 | Paul Stuka | Director | Buy | — | — |
| 2025-12-08 | Paul Stuka | Director | Buy | — | — |
| 2025-12-05 | Paul Stuka | Director | Buy | — | — |
| 2025-11-13 | Paul Stuka | Director | Buy | — | — |
| 2025-10-09 | GARY S ROUBIN | Director | A | — | — |
| 2025-09-17 | Thomas J Kester | Director | A | — | — |
| 2025-08-01 | GARY S ROUBIN | Director | Buy | — | — |
| 2025-08-01 | Thomas J Kester | Director | Buy | — | — |
| 2025-08-01 | Marvin Slosman | CEO and President | Buy | — | — |
| 2025-08-01 | Paul Stuka | Director | Buy | — | — |
| 2025-07-23 | GARY S ROUBIN | Director | X | — | — |
| 2025-07-23 | Thomas J Kester | Director | X | — | — |
| 2025-07-23 | MICHAEL BERMAN | Director | X | — | — |
| 2025-07-23 | Paul Stuka | Director | X | — | — |
| 2025-01-10 | Andrea Tommasoli | Chief Operating Officer | A | — | — |
| 2025-01-10 | Kathryn Arnold | Director | A | — | — |
| 2025-01-10 | Craig Shore | CFO and CAO | A | — | — |
| 2025-01-10 | Marvin Slosman | CEO and President | A | — | — |
| 2025-01-10 | MICHAEL BERMAN | Director | A | — | — |
| 2025-01-10 | Paul Stuka | Director | A | — | — |
| 2025-01-10 | Shane Thomas Gleason | Chief Commercial Officer | A | — | — |
| 2025-01-10 | GARY S ROUBIN | Director | A | — | — |
| 2025-01-10 | Thomas J Kester | Director | A | — | — |
| 2025-01-10 | Patrick Verta | EVP Clinical/Medical Affairs | A | — | — |
| 2025-01-10 | Scott R. Ward | Director | A | — | — |
| 2024-06-26 | MICHAEL BERMAN | Director | X | — | — |
| 2024-06-25 | Thomas J Kester | Director | X | — | — |
| 2024-06-07 | Paul Stuka | Director | X | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and President | 3,556,658 | — |
| — | CFO and CAO | 1,112,460 | — |
| — | Chief Commercial Officer | 1,092,119 | — |
| — | Director | 1,091,575 | — |
| — | Chief Operating Officer | 954,389 | — |
| — | Director | 834,478 | — |
| — | Chief Financial Officer | 691,695 | — |
| — | Director | 597,580 | — |
| — | Director | 458,573 | — |
| — | EVP Clinical/Medical Affairs | 311,532 | — |
| — | Director | 303,087 | — |
| — | Director | 237,096 | — |
| — | Director | 102,047 | — |
| — | Director | 92,417 | — |
| — | Director | 2 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NSPR quote page; the site-wide leaderboard is on the insider transactions hub.